Login / Signup

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.

Mark N SteinLawrence FongRonald TutroneAnthony MegaElaine T LamMegan ParsiSurya VangalaAndres A GutierrezNaomi B Haas
Published in: The oncologist (2022)
NCT02325557.
Keyphrases
  • open label
  • phase ii
  • squamous cell carcinoma
  • small cell lung cancer
  • clinical trial
  • advanced non small cell lung cancer
  • study protocol
  • combination therapy
  • replacement therapy
  • tyrosine kinase